Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Balatonfüred, Budapest III, Budapest IV, Budapest VIII, Budapest X, Budapest XIII, Budapest XIV, Debrecen, Encs, Kecskemét, Kistarcsa, Nyíregyháza, Szeged, Székesfehérvár, and Zalaegerszeg, HungarySee the 15 sites
- Phase
- Phase 3
Where in Hungary
- DRC Kft.Balatonfüred, HungaryTaking people
- Szent Margit Rendelointezet Nonprofit Kft.Budapest III, HungaryTaking people
- Ujpesti EgeszsegkoezpontBudapest IV, HungaryTaking people
- ClinDiab Kft.Budapest VIII, HungaryTaking people
- PVN Kutato Kft.Budapest X, HungaryTaking people
- Central Hospital Of Northern Pest Military HospitalBudapest XIII, HungaryTaking people
- Cardiogeneral Kft.Budapest XIV, HungaryTaking people
- University of DebrecenDebrecen, HungaryTaking people
- CRU Hungary Kft.Encs, HungaryTaking people
- KomplexLabor Kft.Kecskemét, HungaryTaking people
- Kistarcsai Flor Ferenc KorhazKistarcsa, HungaryTaking people
- Szabolcs Szatmár Bereg Vármegyei OktatókórházNyíregyháza, HungaryTaking people
- University of SzegedSzeged, HungaryTaking people
- Regia Med KftSzékesfehérvár, HungaryTaking people
- Zala Varmegyei Szent Rafael KorhazZalaegerszeg, HungaryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.